In 2019, Guerrero et al. discovered novel and selective KOR inhibitors demonstrating potential application in migraine and stress-related mood disorders (e.g., anxiety, depression and drug abuse) treatment [156]. Here, OPRK1 is linked to depressive symptom measurement.